{
    "clinical_study": {
        "@rank": "43443", 
        "arm_group": [
            {
                "arm_group_label": "IQP-CL-101", 
                "arm_group_type": "Active Comparator", 
                "description": "2 softgels twice a day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 softgels twice a day"
            }
        ], 
        "brief_summary": {
            "textblock": "After 2 weeks of run-in period, subjects are randomized to either IQP-CL-101 or a matching\n      placebo. Over 8 weeks, the subjects are monitored for improvements in IBS symptoms"
        }, 
        "brief_title": "IQP-CL-101 in IBS Management", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fulfils Rome-III criteria for IBS diagnosis\n\n          -  Females' agreement to use appropriate birth control methods during the active study\n             period for females of childbearing potential\n\n          -  Subject declares in writing his/her consent to participate, understands requirements\n             of the study and is willing to comply\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to any of the ingredients of IQP-CL-101\n\n          -  Clinically relevant abnormalities in colonoscopy within the last 2 years prior to\n             randomization\n\n          -  Other causes of IBS symptoms such as inflammatory bowel disease (IBD), microscopic\n             colitis, celiac disease, history of abdominal obstruction, cholecystitis,\n             pancreatitis, ileus, or any gastrointestinal bleeding\n\n          -  Use of medications that could influence GI functions (e.g. antibiotics, laxatives,\n             opioids, glucocorticoids, anticholinergics, or anti-diarrheals) within 1 month prior\n             to randomization\n\n          -  Clinically relevant excursions of safety parameters\n\n          -  Any other conditions deemed relevant by the investigator(s)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774825", 
            "org_study_id": "INQ/028111"
        }, 
        "intervention": [
            {
                "arm_group_label": "IQP-CL-101", 
                "description": "2 softgels twice a day", 
                "intervention_name": "IQP-CL-101", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "2 softgels twice a day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Irritable bowel syndrome", 
            "IBS"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10709"
                }, 
                "name": "Barbara Grube"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)", 
        "overall_official": {
            "affiliation": "Private practice", 
            "last_name": "Barbara Grube, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The questionnaire is to be completed by the subject", 
            "measure": "IBS-SSS (Severity Symptom Score)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774825"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The questionnaire is to be completed by the subject", 
                "measure": "IBS-GIS (Global Improvement Score)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The questionnaire is to be completed by the subject", 
                "measure": "IBS-QOL (Quality of Life)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The diary is to be completed by the subject on a daily basis", 
                "measure": "Pain and discomfort diary", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The investigator rates the efficacy of the investigational product using a 4-point Likert scale (poor, moderate, good, very good)", 
                "measure": "Efficacy assessment by investigator", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The subject rates the efficacy of the investigational product using a 4-point Likert scale (poor, moderate, good, very good)", 
                "measure": "Efficacy assessment by subject", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "After sampling, venous blood samples will be transported on same day in cooler boxes to a central laboratory for analysis of hemoglobin, hematocrit, erythrocytes, thrombocytes, and leucocytes", 
                "measure": "Full blood count", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Venous blood samples are obtained at screening and the end of the study (8 weeks)", 
                "measure": "Clinical chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The samples will be later tested by an enzyme immunoassay (ELISA) specific for calprotectin", 
                "measure": "Fecal calprotectin", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Sitting blood pressure and heart rate will be measured using standard devices", 
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The subject rates the safety of the IP using a 4-point Likert scale (poor, moderate, good, very good)", 
                "measure": "Safety assessment by subject", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "The investigator rates the safety of the IP using a 4-point Likert scale (poor, moderate, good, very good)", 
                "measure": "Safety assessment by investigator", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "At all visits, subjects will be asked if any AE has occurred; such events will be recorded in the source documents and case report forms", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}